Treatment of diabetes mellitus with amylin agonists

• US 5,175,145 A
• Filed: 01/14/1992
• Issued: 12/29/1992
• Est. Priority Date: 08/26/1988
• Status: Expired due to Term

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Cooper, Garth J. S.
• Primary Examiner(s): LEE, LESTER
• Application Number:
  US07/821,479
• Time in Patent Office: 350 Days
• Field of Search: 514/4, 514/12
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/225 Calcitonin gene related peptide
• CPC Class Codes: A61K 38/28 Insulins

Abstract

Novel methods for treating diabetes mellitus and hyperglycemia are described which comprise administering to a diabetic or hypoglycemic subject an amount of an amylin agonist effective to induce amylin activity in said subject. Various amylin agonist compounds, and therapeutic methods utilizing such compounds, are also disclosed.

Claims

1. A method of treating diabetes mellitus in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.

2. The method of claim 1 wherein said amylin agonist is amylin.

3. The method of claim 1 wherein said amylin agonist is CGRP.

4. The method of claim 1 wherein said amylin agonist is a conservative variant of amylin.

5. The method of claim 1 wherein said amylin agonist is a conservative variant of CGRP.

6. The method of claim 2 wherein said amylin is human amylin.

7. The method of claim 3 wherein said CGRP is human CGRP.

15. The method of claim 1 or 8 further comprising administering a predetermined amount of an insulin to said subject.

20. The method of claim 1 or 8 wherein said amylin agonist is administered parenterally.

21. The method of claim 15 wherein said insulin is administered parenterally.

23. The method of claim 1 or 8 wherein amylin agonist is administered in a vehicle suitable for delayed release administration.

24. The method of claim 15 wherein said insulin is administered in a vehicle suitable for delayed release administration.

8. A method of treating hypoglycemia in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.

9. The method of claim 8 wherein said amylin agonist is amylin.

10. The method of claim 8 wherein said amylin agonist is CGRP.

11. The method of claim 8 wherein said amylin agonist is a conservative variant of amylin.

12. The method of claim 8 wherein said amylin agonist is a conservative variant of CGRP.

13. The method of claim 9 wherein said amylin is human amylin.

14. The method of claim 10 wherein said CGRP is human CGRP.

16. A method of treating diabetes mellitus comprising administering a pharmaceutical composition comprising an amylin agonist and an insulin.

17. The method of claim 16 wherein the molar ratio of said insulin to said amylin agonist is from 100:

1 to 0.1;

1.

18. The method of claim 16 wherein said amylin agonist is amylin.

19. The method of claim 18 wherein said amylin is human amylin.

22. The method of claim 16 wherein said composition is administered parenterally.

25. The method of claim 16 wherein said composition is administered in a vehicle suitable for delayed release administration.